Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Early initiation of antiosteoporosis therapy cuts risk of hip fracture-related hospitalization

Key clinical point: Late initiation of antiosteoporosis medications (AOMs) is associated with a significantly increased risk of subsequent osteoporotic fracture-related hospitalizations compared with early initiation after an index hip fracture.

Major finding: Late initiation of AOMs (after 252 days) was associated with an increased risk of subsequent osteoporotic fracture-related hospitalization compared with early initiation (on or before 14 days) (hazard ratio [HR], 1.93; P = .001). Among patients with high adherence to AOMs, late initiation was associated with a significantly higher risk of fracture-related hospitalization compared with early initiation (HR, 2.56; P = .002).

Study details: A nationwide cohort study included 9,986 patients who were admitted to the hospital for hip fracture and were prescribed AOMs within 1 year of cohort entry date.

Disclosures: This study was supported by the Ministry of Science and Technology, Executive Yuan of Taiwan, and Research Assistantships funded by the Ministry of Science and Technology, Taiwan, and National Taiwan University Hospital, Yun-Lin. CY Wang received a scholarship from the XinChen Medical Research Foundation, Taiwan. The remaining authors declared no conflicts of interest.

Citation:

Wang CY et al. Bone. 2020 May 25. doi: 10.1016/j.bone.2020.115452.